Building on these observational insights, randomized interventional trials oftargeted anti-inflammatory agents (for example, IL-6 or TNF-αinhibitors) in BD populations, and conversely, adjunctive mood-stabilizingtherapies like lithium in IBD cohorts, should be designed with rigorouspsychiatric and gastrointestinal endpoints [43, 46]. The gene discussed is IL6; the disease is inflammatory bowel disease.